0.00
0.00%
Close of 9 Nov 2026, in AUD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About ImpediMed
Its shares trade on ASX under the ticker IPD.AX. It has been listed since 24 October 2007. In the fiscal year to 30 June 2026, it reported revenue of A$14.6m and a net loss of A$24.9m. At that date it held total assets of A$34.7m and shareholders' equity of A$10.2m.
ImpediMed Ltd. engages in the development and distribution of bioimpedance devices with a focus on medical applications in the fluid status area. The company is headquartered in Brisbane, Queensland. The company went IPO on 2007-10-24. The principal activities of the Company consist of the development, manufacture and sale of bioimpedance instruments and consumables, and the sale of electronic test and measurement devices. The firm's operating segments include Medical, and Test & Measurement. The Medical segment is a supplier of non-invasive medical devices to over two underserved markets: aiding in the subclinical assessment of individuals at risk of secondary lymphedema, and the monitoring of body composition and hydration. The medical cash-generating unit (CGU) is the core business of the Company. The Test & Measurement segment is a supplier of power precision testing and measuring equipment (T&M). The firm's geographical locations include Australia/rest of world (ROW) and North America.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 24 Oct 2007
- Employees
- 67
- Website
- impedimed.com ↗
Leadership
Pay as last reported
- Ms. Christine Emmanuel-DonnellyNon-Executive Independent Chairman of the BoardA$116,972
- Dr. Parmjot BainsInterim Chief Executive Officer, Managing Director, Executive Director, since 2024A$433,696
- Mr. Mcgregor GrantChief Financial & Operating Officer, Executive Director, since 2023A$584,094
- Mr. Tim BenkovicSenior Vice President - Sales and Customer Success
- Mr. Dennis SchlahtSenior Vice President - R&D and TechnologyA$704,203
- Ms. Julie KuhlkenSenior Director, Downstream Marketing
- Ms. Ashley MunozDirector of Human Resources
- Mr. Steven ChenChief Medical Officer
- Ms. Leanne RalphCompany Secretary
- Mr. Andrew GrantDirector, since 2023A$86,087
- Ms. Fiona BonesNon-Executive Independent DirectorA$6,641
- Ms. Janelle DelaneyNon-Executive Independent DirectorA$83,983
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 29
- Environment
- 5
- Social
- 55
- Governance
- 28
- Women in the workforce
- 46.98795%
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- ImpediMed Ltd possesses a unique technology that enables the non-invasive assessment of physiological conditions through bioimpedance spectroscopy. This technology has allowed the development of innovative products that have the potential to revolutionize various medical fields.
- ImpediMed Ltd holds a robust intellectual property portfolio, including patents and trademarks, which provide competitive advantages and barriers to entry for potential competitors. This strengthens the company's position in the market and enhances its ability to protect its innovative technology.
- ImpediMed Ltd has successfully established a strong market presence by partnering with healthcare institutions and professionals worldwide. Its products have gained recognition for their accuracy and effectiveness, contributing to the company's reputation and brand value.
Weaknesses
- ImpediMed Ltd heavily relies on strategic partnerships for distribution, marketing, and sales of its products. This dependency imposes a level of vulnerability on the company, as any disruptions or termination of partnerships could adversely impact its revenue and growth prospects.
- While ImpediMed Ltd has made significant progress in expanding its market presence, there is still room for improvement in terms of market penetration. The company needs to further strengthen its marketing efforts and expand its customer base to drive greater adoption of its products.
Opportunities
- The increasing preference for non-invasive medical technologies presents a significant opportunity for ImpediMed Ltd. With its unique bioimpedance spectroscopy technology, the company is well-positioned to meet the rising demand for accurate and non-invasive physiological assessments across various medical disciplines.
- ImpediMed Ltd has the potential to expand its product offerings into new markets beyond its current focus areas. By identifying and targeting untapped markets, the company can diversify its revenue streams and reduce its dependence on specific regions or segments, thereby enhancing its growth prospects.
Threats
- ImpediMed Ltd operates in a highly competitive industry, facing competition from both established medical device companies and emerging startups. The presence of numerous competitors increases the risk of pricing pressures and the need for continuous innovation to differentiate the company's products from others in the market.
- The medical device industry is subject to strict regulatory requirements, which can pose challenges for product development, approvals, and commercialization. Additionally, reimbursement policies and limitations imposed by healthcare payers may impact the adoption and utilization of ImpediMed Ltd's products, potentially hindering market growth.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.